Ngema Lindokuhle M, Adeyemi Samson A, Marimuthu Thashree, Ubanako Philemon N, Ngwa Wilfred, Choonara Yahya E
Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland 21218, United States.
ACS Omega. 2023 Dec 22;9(1):700-713. doi: 10.1021/acsomega.3c06489. eCollection 2024 Jan 9.
The design of targeted antiangiogenic nanovectors for the delivery of anticancer drugs presents a viable approach for effective management of nonsmall-cell lung carcinoma (NSCLC). Herein, we report on the fabrication of a targeted delivery nanosystem for paclitaxel (PTX) functionalized with a short antimatrix metalloproteinase 2 (MMP-2) CTT peptide for selective MMP-2 targeting and effective antitumor activity in NSCLC. The fabrication of the targeted nanosystem (CLA-coated PTX-SPIONs@CTT) involved coating of superparamagnetic iron-oxide nanoparticles (SPIONs) with conjugated linoleic acid (CLA) via chemisorption, onto which PTX was adsorbed, and subsequent surface functionalization with carboxylic acid groups for conjugation of the CTT peptide. CLA-coated PTX SPIONs@CTT had a mean particle size of 99.4 nm and a PTX loading efficiency of ∼98.5%. The nanosystem exhibited a site-specific in vitro PTX release and a marked antiproliferative action on lung adenocarcinoma cells. The CTT-functionalized nanosystem significantly inhibited MMP-2 secretion by almost 70% from endothelial cells, indicating specific anti-MMP-2 activity. Treatment of tumor-bearing mice with subcutaneous injection of the CTT-functionalized nanosystem resulted in 69.7% tumor inhibition rate, and the administration of the nanosystem subcutaneously prolonged the half-life of PTX and circulation time in vivo. As such, CLA-coated PTX-SPIONs@CTT presents with potential for application as a targeted nanomedicine in NSCLC management.
设计用于递送抗癌药物的靶向抗血管生成纳米载体,为有效治疗非小细胞肺癌(NSCLC)提供了一种可行的方法。在此,我们报告了一种用于紫杉醇(PTX)的靶向递送纳米系统的制备,该系统用短的基质金属蛋白酶2(MMP-2)CTT肽功能化,用于选择性靶向MMP-2并在NSCLC中具有有效的抗肿瘤活性。靶向纳米系统(CLA包被的PTX-SPIONs@CTT)的制备包括通过化学吸附用共轭亚油酸(CLA)包被超顺磁性氧化铁纳米颗粒(SPIONs),在其上吸附PTX,随后用羧酸基团进行表面功能化以偶联CTT肽。CLA包被的PTX SPIONs@CTT的平均粒径为99.4 nm,PTX负载效率约为98.5%。该纳米系统在体外表现出位点特异性的PTX释放以及对肺腺癌细胞明显的抗增殖作用。CTT功能化的纳米系统显著抑制内皮细胞分泌MMP-2近70%,表明具有特异性抗MMP-2活性。对荷瘤小鼠皮下注射CTT功能化的纳米系统进行治疗,肿瘤抑制率达69.7%,皮下给药该纳米系统可延长PTX在体内的半衰期和循环时间。因此,CLA包被的PTX-SPIONs@CTT具有作为靶向纳米药物用于NSCLC治疗的潜力。